Personalizing aerosol medicine: Development of delivery systems tailored to the individual

Therapeutic Delivery

Volumn 1, Issue 5, 2010, Pages 667-682

  Cipolla, David ^a   Chan, Hak Kim ^b   Schuster, Jeffrey ^c   Farina, Dino ^d  

^a ARADIGM CORPORATION   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Proveris Scientific Corporation ^*  (United States)

^d Proveris Scientific Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AEROSOL; DEVICE SAFETY; EQUIPMENT DESIGN; ERGOMETRY; HEALTH CARE COST; HUMAN; INHALER; LUNG DISEASE; MEDICAL NEBULIZER; METERED DOSE INHALER; PATIENT ASSESSMENT; POWDER INHALER; PRIORITY JOURNAL; PROSPECTIVE PRICING; REIMBURSEMENT; REVIEW; SOLUTION INHALER; SPIROMETRY;

EID: 79954515565     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.10.54     Document Type: Review

References (90)

1. Collins FS. The language of life: DNA and the revolution in personalized medicine. Harper Collins Publishers, NY, USA (2010).
2. Goetz T. The decision tree: taking control of your health in the new era of personalized medicine. Rodale Books (2010).
3. Davies K. Proselytizing personalized medicine. Bio-9(2), 52010).
4. Melani AS. Inhalatory therapy training: a priority challenge for the physician. Acta Biomed. 78, 233-245 (2007). (Pubitemid 351599006)
5. Crompton GK, Barnes PJ, Broeders M, et al. The need to improve inhalation technique in Europe: a report from the Aerosol Drug Management Improvement Team. Respir. Med. 100(9), 1479-1494 (2006). (Pubitemid 44109117)
6. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 127(1), 335-371 (2005). (Pubitemid 41724594)
7. Sestini P, Cappiello V, Aliani M, et al. Prescription bias and factors associated with improper use of inhalers. J. Aerosol Med. 19(2), 127-136 (2006). (Pubitemid 43993379)
8. Mitchell JP, Nagel MW. Oral inhalation therapy: meeting the challenge of developing more patient-appropriate devices. Expert Rev. Med. Devices. 6(2), 147-155 (2009).
9. Everard ML. Regimen and device compliance: key factors in determining therapeutic outcomes. J. Aerosol Med. 19(1), 67-73 (2006).
10. Newman S. The background to pulmonary drug delivery in man. In: Respiratory Drug Delivery: Essential Theory and Practice. Newman S. Respiratory Drug Delivery Online, Richmond, VA, USA 1-28 (2009).
11. Borgstrom L, Olsson B, Thorsson L. Degree of throat deposition can explain the variability in lung deposition of inhaled drugs. J. Aerosol Med. 19(4), 473-483 (2006). (Pubitemid 46067766)
12. Melani AS, Zanchetta D, Barbato N, et al. Inhalation technique and variables associated with misuse of conventional metered-dose inhalers and newer dry powder inhalers in experienced adults. Ann. Allergy Asthma Immunol. 93(5), 439-446 (2004). (Pubitemid 39507710)
13. Lavorini F, Magnan A, Dubus JC, et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Resp. Med. 102, 593-604 (2008).
14. Dolovich MB. In my opinion - interview with the expert. Pediatr. Allergy Immunol. 17(4), 292-300 (2004). (Pubitemid 40224135)
15. Molimard M, Rahersion C, Lignot S, et al. Assessment of handling of inhaler devices in real life: an observational study in patients in primary care. J. Aerosol Med. 16, 249-254 (2003). (Pubitemid 37169635)
16. Heslop K. Respiratory inhaled therapy 2: choosing an inhaler. Nursing Times 105, 13 (2009).
17. Kamen WES, Genz T, Roeder S, et al. The inhalation manager: a new computer-based device to assess inhalation technique and drug delivery to the patient. J. Aerosol Med. 16, 21-29 (2003). (Pubitemid 36457650)
18. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch. Intern. Med. 169(3), 219-229 (2009).
19. Krigsman K, Moen J, Nilsson JL, Ring L. Refill adherence by the elderly for asthma/chronic obstructive pulmonary disease drugs dispensed over a 10-year period. J. Clin. Pharm. Ther. 32(6), 603-611 (2007). (Pubitemid 350135114)
20. Aspinall MG and Hamermesh RG. Realizing the promise of personalized medicine. Harvard Business Review, October, 108-117 (2007).
21. Safeer RS, Keenan J. Health literacy: the gap between physicians and patients. American Family Physician 72(3), 463-468 (2005). (Pubitemid 41099526)
22. Roberts NJ, Ghiassi R, Partridge MR. Health literacy in COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 3(4), 499-507 (2008).
23. McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what this means. Pharmacoeconomics 26(9), 733-744 (2008).
24. Thiel CG. From Susie's question to CFC free: an inventor's perspective on forty years of MDI development and regulation. In: Respiratory Drug Delivery V, Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ (Eds). Interpharm Press, Buffalo Grove, IL, USA, 115-123 (1996).
25. Newman S, Peart J. Pressurized metered dose inhalers. In: Respiratory Drug Delivery: Essential Theory and Practice. Newman S. Respiratory Drug Delivery Online, Richmond, VA, USA 177-215 (2009).
26. Stein S, Fradley G. What is the future of MDIs? In: Respiratory Drug Delivery 2010, Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM (Eds). Davis Healthcare International Publishing, LLC, River Grove, IL, USA 373-376 (2010).
27. Brennan VK, Osman LM, Graham H, Critchlow A, Everard ML. True device compliance: the need to consider both competence and contrivance. Respir. Med. 99(1), 97-102 (2005). (Pubitemid 40017391)
28. Rubin BK, Fink JB. Optimizing aerosol delivery by pressurized metered-dose inhalers. Respir. Care. 50, 1191-1200 (2005).
29. Borgstrom L, Derom E, Stahl E, Wahlin-Boll E, Pauwels R. The inhalation device influences lung deposition and bronchodilating effect of terbutaline. Am. J. Respir. Crit. Care Med. 153, 1636-1640 (1996). (Pubitemid 26141353)
30. Devadason SG, Le Souef PN. Age-associated factors influencing the efficiency of various forms of aerosol therapy. J. Aerosol Med. 15(3), 343-345 (2002). (Pubitemid 34983140)
31. Woodcock A. Responsible inhaler development in article 5 countries: navigating the scientific, regulatory, political and commercial challenges. In: Respiratory Drug Delivery 2010, Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM (Eds). Davis Healthcare International Publishing, LLC, River Grove, IL, USA 121-129 (2010).
32. Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur. Respir. J. 12, 1346-1353 (1998). (Pubitemid 29011427)
33. Newman SP. Improving drug metering to the lung: making the patient the most important factor. In: Respiratory Drug Delivery 2006, Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ (Eds). Davis Healthcare International Publishing, LLC, River Grove, IL, USA 1-12 (2006).
34. Newman S. Additional technology for pressurized metered-dose inhalers. In: Respiratory Drug Delivery: Essential Theory and Practice. Newman S. Respiratory Drug Delivery Online, Richmond, VA, USA 217-256 (2009).
35. Shrewsbury S, Mohsen N, Newman S, Pitcairn G, Armer T. Novel aerosol delivery of fluticasone propionate via the Tempo™ inhaler in humans. International Society for Aerosols in Medicine (ISAM) 16th Congress, Abstract P027, J. Aerosol Med. 20(2), 172 (2007).
36. Armer TA, Shrewsbury SB, Newman SP, Pitcairn G, Ramadan N. Aerosol delivery of ergotamine tartrate via a breath-synchronized plume-control inhaler in humans. Curr. Med. Res. Opin. 23(12), 3177-3187 (2007).
37. SmartMist™ Respiratory Management System User Guide. (1997).
38. Farr SJ, Rowe AM, Rubsamen R, Taylor G. Aerosol deposition in the human lung following administration from a microprocessor controlled pressurized metered dose inhaler. Thorax. 50, 639-644 (1995).
39. Newman S, Peart J. Dry powder inhalers. In: Respiratory Drug Delivery: Essential Theory and Practice. Newman S. Respiratory Drug Delivery Online, Richmond, VA, USA 257-307 (2009).
40. Weers JG, Tarara TE, Clark AR. Design of fine particles for pulmonary drug delivery. Expert Opin Drug Del. 4, 297-313 (2007). (Pubitemid 46772848)
41. Weers JG, Bell J, Chan HK, et al. Pulmonary formulations: what remains to be done? J. Aerosol Med. Pulm. Drug Del. (Suppl. 2), S1-S19 (2010).
42. Van der Palen J, Klein JJ, Van Herwaarden CLA, Zielhuis GA, Seydel ER. Multiple inhalers confuse asthma patients. Eur. Respir. J. 14, 1034-1037 (2000).
43. Chew NYK, Chan H-K. In vitro aerosol performance and dose uniformity between the Foradile® Aerolizer® and the Oxis® Turbuhaler®. J. Aerosol Med. 14, 495-501 (2001). (Pubitemid 34008106)
44. Haughney J, Price D, Barnes NC, Virchow JC, Roche N, Chrystyn H. Choosing inhaler devices for people with asthma: current knowledge and outstanding research needs. Respir. Med. 104(9), 1237-1245 (2010).
45. Everard ML. Inhaler devices in infants and children: challenges and solutions. J. Aerosol Med. 17, 186-195 (2004). (Pubitemid 38955680)
46. Virchow JC, Crompton GK, Dal Negro R, et al. Importance of inhaler devices in the management of airway disease. Respir. Med. 102, 10-19 (2008). (Pubitemid 350161842)
47. Self TH, Pinner NA, Sowell RS, Headley AS. Does it really matter what volume to exhale before using asthma inhalation devices? J. Asthma 46, 212-216. (2009).
48. Kohler D. The Novolizer®: overcoming inherent problems of dry powder inhalers. Respir. Med. Supplement A. S17-S21 (2004). (Pubitemid 38578717)
49. Rönmark E, Jogi R, Lindqist A, et al. Correct use of three powder inhalers: comparison between Diskus, Turbuhaler, and Easyhaler. J. Asthma. 42, 173-178 (2005). (Pubitemid 40776961)
50. Molimard M, Raherison C, Lignot S, Depont F, Abouelfath A, Moore N. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J. Aerosol Med. 16, 249-254 (2003). (Pubitemid 37169635)
51. Kim S-H, Kwak HJ, Kim T-B, et al. Inappropriate techniques used by internal medicine residents with three kinds of inhalers (a metered dose inhaler, Diskus, and Turbuhaler): changes after a single teaching session. J. Asthma 46, 944-950 (2009).
52. Newman S. Nebulizers. In: Respiratory Drug Delivery: Essential Theory and Practice. Newman S. Respiratory Drug Delivery Online, Richmond, VA, USA 135-175 (2009).
53. Cipolla D, Boyd B, Evans R, Warren S, Taylor G, Farr S. Bolus administration of INS365: studying the feasibility of delivering high dose drugs using the AERx Pulmonary Drug Delivery System. In: Respiratory Drug Delivery VII, Dalby RN, Byron PR, Farr SJ, Peart J (Eds), Serentec Press, Inc, Raleigh, NC, USA 231-239 (2000).
54. Weers J, Metzheiser B, Taylor G, Warren S, Meers P, Perkins WR. A g-scintigraphic study to investigate lung deposition and clearance of inhaled amikacin-loaded liposomes in healthy male volunteers. J. Aerosol Med. Pulm. Drug Del. 22(2), 131-138 (2009).
55. Newman SP, Pitcairn GR, Pickford M, et al. Pharmacoscintigraphy of TOBI in the Pari LC Plus and the AeroDose inhaler. J. Aerosol Med. 14, 388 Abstract (2001).
56. Behr J, Zimmermann G, Baumgartner R, et al. Lung deposition of a liposomal cyclosporine A inhalation solution in patients after lung transplantation. J. Aerosol Med. Pulm. Drug Del. 22(2), 121-129 (2009).
57. Coates AL, Green M, Leung K, et al. The challenges of quantitative deposition using 99mTc-DTPA from delivery systems with very different delivery times. J. Aerosol Med. Pulm. Drug Del. 20(3) 320-330 (2007). (Pubitemid 47463185)
58. Ghazanfari T, Elhissi AM, Ding Z, Taylor KM. The influence of fluid physicochemical properties on vibrating-mesh nebulization. Int. J. Pharm. 339(1-2), 103-111 (2007). (Pubitemid 46977598)
59. Denyer J, Dyche T. The adaptive aerosol delivery (AAD) technology: past, present and future. J. Aerosol Med. Pulm. Drug Del. 23(S1), S1-S10 (2010).
60. Nikander K, Denyer J. Adaptive aerosol delivery (AAD) technology. In: Modified Release Drug Delivery Technology, 2nd Edition. Ratthbone MJ (Ed.). Informa Healthcare USA, Inc., NY, USA 603-612 (2008).
61. Nikander K, Prince I, Coughlin S, Warren S, Taylor G. Mode of breathing - tidal or slow and deep - through the I-neb adaptive aerosol delivery (AAD) system affects lung deposition of 99mTc-DTPA. J. Aerosol Med. Pulm. Drug Del. 23(S1), S37-S44 (2010).
62. Goodman N, Morgan M,Nikander K, Hinch S, Coughlin S. Evaluation of patient-recorded outcomes and quality of life with the I-neb adaptive aerosol delivery (AAD) system in patients with chronic obstructive pulmonary disease. J. Aerosol Med. Pulm. Drug Del. 23(S1), S61-S70 (2010).
63. Nikander K, Denyer J, Dodd M, et al. The adaptive aerosol delivery system in a telehealth setting: patient acceptance, performance and feasibility. J. Aerosol Med. Pulm. Drug Del. 23(S1), S21-S28 (2010).
64. Wachtel H, Moser A. The Respimat®, a new soft mist inhaler for delivering drugs to the lungs. In: Modified Release Drug Delivery Technology, 2nd Edition. Ratthbone MJ (Ed). Informa Healthcare USA, Inc., NY, USA 637-646 (2008).
65. Newman S. Emerging Inhaler technologies. In: Respiratory Drug Delivery: Essential Theory and Practice. Newman S. Respiratory Drug Delivery Online, Richmond, VA, USA 309-336 (2009).
66. Cipolla DC, Johansson E. AERx pulmonary drug delivery systems. In: Modified Release Drug Delivery Technology, 2nd Edition. Ratthbone MJ (Ed.). Informa Healthcare USA, Inc., New York, NY, USA 563-571 (2008).
67. Rottier BL, van Erp CJP, Sluyter TS, et al. Changes in performance of the PARI eFlow Rapid and PARI LC Plus during 6 months use by CF patients. J. Aerosol Med. Pulm. Drug Del. 22(3), 263-269 (2009).
68. Perkins W, Coates AL, Rottier BL, de Boer AH. Performance of the PARI eFlow. J. Aerosol Med. Pulm. Drug Del. 23(2), 113-118 (Correspondence to the Editor) (2010).
69. Cipolla DC, Dayton F, Fulzele S, et al. Inhaled liposomal ciprofloxacin: in vitro properties and aerosol performance. In: Respiratory Drug Delivery 2010. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM (Eds). Davis Healthcare Int. Publishing LLC, River Grove, IL, USA 409-414 (2010).
70. Noymer P, Schuster J, Holst P, et al. AERx-Essence: efficiency and breath control without electronics. In: Respiratory Drug Delivery 2010. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM (Eds). Davis Healthcare International Publishing, LLC, River Grove, IL, USA 255-262 (2004).
71. Mullinger B, Topini TC, Valeri AL, et al. Choice of nebulizer for inhaled tobramycin treatment in cystic fibrosis. In: Respiratory Drug Delivery 2010. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM (Eds). Davis Healthcare Int. Publishing LLC, River Grove, IL, USA 385-389 (2010).
72. Noymer P, Myers D, Glazer M, Fishman R, Cassella J. The Staccato System: inhaler design characteristics for rapid treatment of CNS disorders. In: Respiratory Drug Delivery 2010. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM (Eds). Davis Healthcare Int. Publishing LLC, River Grove, IL, USA 11-19 (2010).
73. Dinh KV, Myers DJ, Noymer PD, Cassella JV. In vitro aerosol deposition in the oropharyngeal region for Stoccato® Loxapine. J. Aer. Med. Pulm. Drug Del. 23(4), 253-260 (2009).
74. Taylor G. Pulmonary delivery by AERX: reducing variability in lung deposition and absorption. Presented at: The International Society for Aerosols in Medicine (ISAM) 14th Congress. Baltimore, MD, USA 14-18 June 2003.
75. Gauthier WD, et al. Apparatus for inhalation. therapy. US3387607 (1968).
76. Michaels AS, Buckles RG, Kelier MP. Ultrasonic nebulizer. US3812854 (1974).
77. Global Initiative for Asthma, guidelines www.ginasthma.com/Guidelineitem. aspl1=2&l2=1&intId=1561
78. Chronic obstructive pulmonary disease, guidelines. www.goldcopd.com/ Guidelineitem. asp?l1=2&l2=1&intId=996
79. National Cancer Institute. Pink book - making health communication programs work (2008). www.cancer.gov/pinkbook
80. Friederiszick H, Tosini N, de Vericourt F, Wakeman S. An economic assessment of the relationship between price regulation and incentives to innovate in the pharmaceutical industry. ESMT White paper. No. WP-109-103 (2009). www.esmt.org/eng/faculty-research/white-papers/Center for Health Value Innovation. www.vbhealth.org
81. Bennets inhaler. www.inhalatorium.com/page162.html
82. Pari GmbH historical timeline. www.paripharma.com/about3.htm
83. Google health, pediatric asthma. https://health.google.com/health/ref/ Asthma+-+pediatric
84. Technical details about the operation of the AeroEclipse II BAN. www.trudellmed.com/sites/trudellmed.com/files/pdf/consumer/AEII-VisAidEN.pdf
85. Pari lower airways inhalation devices. www.pari.de/en/products/lower- airways.html
86. MicroDose® technology and features. www.mdtx.com/mdtx/wp-content/ uploads/pdf/MicroDoseDPIDrugDeliveryAug2007.pdf
87. Executive briefing on how healthcare reform may impact the pharmaceutical industry. www.oliverwyman.com/ow/pdf-files/PharmaReform.pdf
88. Instruction manual for the cleaning the Aeroneb Go, pages 11-14. www.evomedical.com/pdf/22263%20 evo%20Aeroneb%20Go%20Manual.pdf
89. Owner's manual for the Omron MicroAir®. Pages 16-20 outline the very extensive cleaning required. www.omronhealthcare.com/img/shop/neu22v20076c2.pdf
90. Pfizer and Keas personal health planning. www.Keas.com